Medication and DNA
Evrota 25-27, Kifisia 145 64
The best treatment
lies within your DNA!
Your genes can indicate
the appropriate medication
A patient’s genetic makeup may influence the effectiveness of medication up to 95%. There have been reported cases of people experiencing serious side effects after taking one drug, while they present no side effects with other drugs. Our genetic profile accounts for inter-individual differences in response to the same drug type and dose by patients with the same disease. We are all different and therefore react in different ways to a specific treatment.
We are all unique and as patients we react differently when receiving a specific treatment.
A simple Pharmacogenetics test can help the physician determine which drug is appropriate for their patient. That is, with which drug, and at what dose the patient will have the best response with the minimum side effects.
Pharmacogenetics combines pharmacology (pharmacokinetics and pharmacodynamics), i.e. the mode of action of drugs in the body in association in association with genetics. Pharmacogenetics Science studies and analyses patients' response to drugs by correlating their gene expression or polymorphisms (SNPs) of their genes with the efficacy or toxicity of a drug.
Several genes directly affect drug metabolism and the consequent therapeutic benefit that a drug may have for a particular patient. This is the rationale behind the different effect that the same drug at the same dose may have on patients with the same disease.
Τα Medical DNA Tests προσφέρουν φαρμακογονιδιωματική ανάλυση και αναφέρονται σε ασθενείς
Οφέλη Medical DNA Τests
Selection of optimal medication
Fewer side effects
Treatment cost reduction
What does the evidence show
It is now known that patients with the same disease respond differently to the same treatment. A patient’s genetic profile plays a key role in treatment response and can influence the effectiveness of patients’ medication up to 95%.
34% of CNS drugs’ side effects are caused by the patient’s genetic profile and not by drug interactions with other drugs.
In the near future, Pharmacogenomics is expected to be a routine procedure in all patients before prescribing antidepressants. This is also the goal for medical practice in psychiatry.
A study in 501 Greek patients, genotyped for three P450 enzymes, showed that a high proportion of patients are expected to exhibit poor or intermediate metabolism of drugs metabolised by one of the P450 enzymes (39% for CYP2C9, 27% for CYP2C19 and 38% for CYP2D6). This is consistent with other Caucasian populations. Similarly, more than 70% of the patients are expected to exhibit intermediate or enhanced gene-drug interactions to a range of CNS drugs.
* Listed above are some of the most representative researches in the Science of Pharmacogenomics
iDNA PGx CNS
iDNA PGx CNS offers Pharmacogenomic analysis of drugs related to Central Nervous System (CNS) diseases. IDNA PGx CNS Test aids the physician in choosing the appropriate personalised treatment: the appropriate drug at the right dose for minimum side effects and optimal patient response.
The iDNA PGx CNS is an in vitro diagnostic (IVD) medical device bearing the CE mark and has been notified to the National Medicines Agency (EOF) Medical Devices Register "Gremdis" (Protocol No. 54854 / 23-05-2022).